Status:
ENROLLING_BY_INVITATION
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy
Lead Sponsor:
AbbVie
Conditions:
Diabetic Retinopathy, DR
Eligibility:
All Genders
Brief Summary
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR wit...
Eligibility Criteria
Inclusion
- Must provide written, signed informed consent for this study
- Must have been enrolled in a previous clinical study of RGX-314 for the treatment of DR without CI-DME and must have received an SCS injection of RGX-314 in that study
- Must be willing and able to comply with all study procedures
Exclusion
- None
Key Trial Info
Start Date :
April 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05296447
Start Date
April 4 2022
End Date
May 1 2028
Last Update
June 18 2025
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Retinal Research Institute, LLC
Phoenix, Arizona, United States, 85014
2
California Retina Consultants
Bakersfield, California, United States, 93309
3
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
4
American Institute of Research
Los Angeles, California, United States, 90017